Pfizer Announces Vaccine Provides Insufficient Protection for Young Children
By Zachary Evans
December 17, 2021 2:47 PM
Pfizer and BioNTech announced on Friday that the companies will modify a clinical trial for their coronavirus vaccine in young children, after a two-dose regimen did not produce a sufficient immune response in children ages 2, 3, and 4.
The companies said that “no safety concerns were identified” in the trial, and that participants age 2-4 will be given a third vaccine dose two months after their second dose. Participants ages six months to 24 months saw a sufficient immune response from the vaccine.
Participants were given 3 micrograms of vaccine, or one-tenth of the dose given to adults over age 18. Pfizer spokeswoman Jerica Pitts said the companies do not plan to increase the dosage for young children, and instead will determine whether a third 3-microgram dose generates sufficient immunity.
“The goal here is to understand the potential of protection of the third dose,” Pitts told the New York Times.
more
https://www.nationalreview.com/news/pfizer-announces-vaccine-provides-insufficient-protection-for-young-children/